Back to top
Search by company, common medicine name, or title of Risk Minimisation Material
For Healthcare Professionals
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan
For Healthcare Professionals
The information provided in this booklet should be discussed with patients (or parents/legal guardians of paediatric patients) by their healthcare professional during MabThera (rituximab) treatment. This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.
For Healthcare Professionals
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.
For Healthcare Professionals
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.
For Healthcare Professionals
A quick reference guide to the appropriate Maloff Protect pack sizes for trips to malaria endemic areas
For Healthcare Professionals
A quick guide to the key actions the pharmacist should take before supplying Maloff Protect
For Healthcare Professionals
This guide provides information on the correct choice and usage of the various malaria chemoprophylaxis, including Maloff Protect
For Healthcare Professionals
A screening questionnaire which the pharmacist can fill out with the customer. It is accompanied by some explanatory notes and together these will help the pharmacist understand if Maloff Protect is suitable for the customer.
For Healthcare Professionals
Along with the User Reminder App, customers can use this Reminder Card to plan their Maloff Protect dosing
For Healthcare Professionals
Website to host materials for physicians to support appropriate prescribing of methylphenidate.
For Healthcare Professionals
Reminder of the potential risk of life-threatening harm from accidental exposure
MAVENCLAD 10 mg Tablets (cladribine) - Patient Guide - Important information on minimising the risk of adverse events
For Healthcare Professionals
MAVENCLAD 10 mg Tablets (cladribine) - Prescriber's Guide - Important information on minimising the risk of adverse events
For Healthcare Professionals
To minimise the risk of overdose from patients incorrectly taking methotrexate daily instead of once weekly for autoimmune diseases
The Patient Card contains important safety information the patient needs to be aware of when receiving treatment with methotrexate for conditions including arthritis and psoriasis
For Healthcare Professionals
Website to host materials for physicians to support appropriate prescribing of methylphenidate
For Healthcare Professionals
A guide for Healthcare Professionals to minimise the risk of overdose from patients incorrectly taking methotrexate daily instead of once weekly for autoimmune diseases.
The Patient Card contains important safety information the patient needs to be aware of when receiving treatment with methotrexate for conditions including arthritis and psoriasis.
For Healthcare Professionals
To minimise the risk of overdose from patients incorrectly taking methotrexate daily instead of once weekly for autoimmune diseases
This Patient Card is only intended for patients taking Methotrexate once a week for conditions including arthritis, psoriasis and Crohn's Disease.
For Healthcare Professionals
To minimise the risk of overdose from patients incorrectly taking methotrexate daily instead of once weekly for autoimmune diseases
For Healthcare Professionals
The Patient Card contains important safety information the patient needs to be aware of when receiving treatment with methotrexate for conditions including arthritis and psoriasis.
For Healthcare Professionals
To minimise the risk of overdose from patients incorrectly taking methotrexate daily instead of once weekly for autoimmune diseases
The Patient Card contains important safety information the patient needs to be aware of when receiving treatment with methotrexate for conditions including arthritis and psoriasis.
For Healthcare Professionals
Educational Materials. Guide for Healthcare Professionals Rosemont Methotrexate 2 mg/ml Oral Solution
For Healthcare Professionals
To minimise the risk of overdose from patients incorrectly taking methotrexate daily instead of once weekly for autoimmune diseases Medicines containing methotrexate are available in a range of presentations, including: oral tablets, oral solutions, vials for injection, pre‐filled syringes and pens for injection, concentrate for solution for injection.
THIS PATIENT CARD IS ONLY INTENDED FOR PATIENTS TAKING METHOTREXATE ONCE A WEEK FOR CONDITIONS INCLUDING ARTHRITIS, PSORIASIS AND CROHN'S DISEASE.
For Healthcare Professionals
Methotrexate Educational Materials for Healthcare Professionals approved by the MHRA
For Healthcare Professionals
Prescribing checklist before prescribing methylphenidate hydrochloride and checklist for ongoing monitoring
For Healthcare Professionals
Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine
For Healthcare Professionals
Combined Hormonal Contraceptives - checklist for prescribers
Combined hormonal contraceptives: Q&As about the important information for women.
Important Information for women about risk of blood clots with combined hormonal contraceptives.
For Healthcare Professionals
Combined Hormonal Contraceptives - checklist for prescribers
Combined hormonal contraceptives: Q&As about the important information for women.
Important Information for women about risk of blood clots with combined hormonal contraceptives.
For Healthcare Professionals
Checklist in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations.
Important information for women about risk of blood clots with combined hormonal contraceptives (CHC).
For Healthcare Professionals
Information for Healthcare Professionals to help inform patients, their families, and their caregivers about the benefits and the risks associated with quetiapine treatment.
For Healthcare Professionals
Healthcare professional brochure to describe risk of ectopic pregnancy and how to differentiate between Bayer levonorgestrel IUS (LNG-IUS)
For Healthcare Professionals
IV iron. Essential Prescription and Administration Information to Minimise the Risk of Serious Hypersensitivity Reactions
Intravenous (IV) Iron. Important Information for Patients about the Possible Risk of Serious Allergic Reactions with IV iron treatment (iron given by injection or infusion into a vein)
For Healthcare Professionals
For hard copies, please contact medical information department at 0800 035 2525 or email [email protected].
For Healthcare Professionals
Healthcare professional guide contains information on the specific risks associated with Myalepta and the measures designed to address them along with the potentially serious adverse drug reactions.
This document contains important risk minimisation information for patients and their carers.
Provides patients and their carers important information on how to reconstitute and administer Myalepta (metreleptin).
For Healthcare Professionals
This brochure is for Specialist Prescribers of Myalepta only and provides guidance on determining the right dose, training the patient to prepare and inject and prescribing.
For Healthcare Professionals
Mycophenolate Guide for Healthcare Professionals- Information about Risk of Teratogenicity
Mycophenolate Guide for Patients Information- about risks to the unborn baby
For Healthcare Professionals
Guide for Healthcare Professionals
For Healthcare Professionals
Guide for Healthcare Professionals
For Healthcare Professionals
This Guide has been designed to highlight the risks to babies associated with exposure to mycophenolate during pregnancy and to minimise the number of pregnancies during treatment with this teratogenic medicinal products. Use this guide during, discussion with the patient to address any questions or concerns the patient may have. Although this Guide presents important information concerning the adverse pregnancy outcomes associated with mycophenolate, please consult the Summary of Product Characteristics (SmPC) for full information on mycophenolate.
This guide will help you to remember the information you have discussed with your doctor. Keep it so that you can refer to it again. Also, read the package leaflet supplied with your medicine for full information on mycophenolate mofetil.
For Healthcare Professionals
This guide has been designed to highlight the risks associated with exposure to mycophenolate during pregnancy, as well as the measures that should be taken to mitigate them.
This guide is about the risks of mycophenolate for the unborn baby, and the ways to reduce these risks.
For Healthcare Professionals
Guidance for healthcare professionals on risks associated with Myozyme (alglucosidase alfa) administration, clinical risk management and immunology testing. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]
For Healthcare Professionals
This checklist is provided by Orexigen Therapeutics Ireland Limited as a requirement under the terms of the marketing authorization for this medicine. This prescriber guide is a reminder of the indication, contraindications, warnings and precautions as well as the patient characteristics that may place patients at higher risk of adverse reactions to Mysimba. This will help ensure appropriate patient selection and remind physicians of patients who should not be prescribed Mysimba or in whom it should be used with caution. This checklist should be completed prior to initiating therapy with Mysimba.
Are you a healthcare professional?
Are you a healthcare professional?
Skip to main content